Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs

Company Overview - Omnicell is a leading provider of automation and information technology solutions for medication and supply management in healthcare settings, leveraging advanced robotics and software integration [6][7] - The company generates revenue primarily through the sale and servicing of hardware, software, and consumables, as well as through recurring service and maintenance contracts [7] - Key customers include healthcare systems, hospitals, institutional pharmacies, and outpatient care providers in the United States and internationally [7] Financial Performance - For the trailing twelve months (TTM), Omnicell reported revenue of $1.18 billion and net income of $19.92 million [4] - The company's stock has experienced a 1-year price change of 3.17% as of January 5, 2026 [4] - The current market capitalization of Omnicell is $2.0 billion, with a gross margin of 43.82% [9] Recent Developments - The company recently launched its Titan XT automated dispensing system, designed to streamline hospital medication workflows and integrate with the cloud-based OmniSphere platform [10] - Following strong Q3 results that exceeded analyst expectations, management raised full-year revenue guidance to between $1.177 billion and $1.187 billion [10] - The stock has rallied significantly from its 52-week low of $22.66 in May, currently trading around $46.95, which is approximately double its May low [9][10] Insider Transactions - Corey J Manley, EVP & Chief Legal/Admin Officer at Omnicell, executed an open-market sale of 6,106 shares for $243,629.40 on December 3, 2025 [1][2] - This sale reduced Manley's direct holdings by 5.85%, leaving him with 98,282 shares, which equates to 0.2122% of the company's shares outstanding [6] - The transaction size was larger than Manley's median recent open-market sales, indicating a continuation of his recent selling activity [6]